Pipotiazine palmitate (19.552 R.P.) in the long-term treatment of chronic psychoses. A controlled trial on in-patients.
D000328:Adult; D000367:Age Factors; D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D007267:Injections; D008297:Male; D008875:Middle Aged; D010169:Palmitic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D010640:Phenothiazines; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013997:Time Factors
D000928:Antidepressive Agents; D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D006993:Hypnotics and Sedatives; D010169:Palmitic Acids; D010640:Phenothiazines; D010880:Piperidines; D013449:Sulfonamides